Mater Interfaces 16, 2817228183
FDA is statutorily mandated to create these lists and issued a Proposed Rule on March 20, 2024, with comments being due by June 18, 2024
No receptor-mediated adverse events (e.g., cardiovascular effects, endocrine disruption) have been reported, consistent with NNMT's limited expression outside metabolic tissues
Lifestyle and dietary modifications form the cornerstone of initial management: Eat smaller, more frequent meals : Rather than three large meals, consider five to six smaller portions throughout the day to reduce gastric distension
It is not an approved drug for human or veterinary use
Available on both iOS and Android